Literature DB >> 17401513

Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.

Alexandra Balbir-Gurman1, Yolanda Braun-Moscovici, Vladimir Livshitz, Daniel Schapira, Doron Markovits, Alexander Rozin, Tatiana Boikaner, A Menahem Nahir.   

Abstract

Oxidative stress is involved in pathogenesis of Raynaud's phenomenon (RP), a hallmark of systemic sclerosis (SSc). Frequent episodes of ischemia-reperfusion may lead to release of free radicals and enhanced lipid peroxidation reflected by elevated levels of malondialdehyde (MDA). The failure of native antioxidants (Catalase [CAT], Superoxide dismutase [SOD], and Ceruloplasmin [CP]) might be crucial in endothelial cells damage in RP. Iloprost (IL) synthetic prostacyclin analogue is currently used in the treatment of SSc patients with RP. The objectives of this study were to compare the serum levels of MDA and CP, CAT and SOD activity in red blood cells hemolysate in SSc patients compared to healthy controls; and to study the effect of 5-days IL infusions on MDA and CP levels, and CAT and SOD activity in SSc patients with RP. Twelve SSc patients were treated with 50 mug IL for 5 days. Blood samples were taken before and after day 1st and after day 5th of IL infusions. Levels of CAT were measured according to the Aebi's method; SOD, according to the Misra and Fridovich method; MDA, according to Slater's method; and CP, according to Ravin's method. Activities of CAT (p < 0.001) and SOD (p < 0.04) were significantly reduced; levels of CP (p < 0.006) and MDA (p < 0.06) were raised in SSc compared to controls. IL infusions caused reduction in MDA (p < 0.0001) levels and enhanced production of SOD (p < 0.006) and CAT (p < 0.003). The levels of CP did not change (p = 0.48). Oxidant status in SSc patients with RP is impaired. Therapy with IL led to normalization of antioxidant activity. We suggest that CAT may be a sensitive and reliable laboratory marker of oxidative stress severity in RP. We found that IL, in addition to its vasoactive properties, has a potential to activate inner antioxidant system. Activation of inner antioxidant activity may explain long-term effect of IL instead of its very short half-life time.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401513     DOI: 10.1007/s10067-007-0613-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

Review 1.  The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis.

Authors:  A L Herrick; M Matucci Cerinic
Journal:  Clin Exp Rheumatol       Date:  2001 Jan-Feb       Impact factor: 4.473

2.  Oxidative stress in Systemic Sclerosis.

Authors:  G Simonini; M M Cerinic; S Generini; M Zoppi; M Anichini; C Cesaretti; A Pignone; F Falcini; T Lotti; M Cagnoni
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

3.  Lipid peroxidation and trace elements in systemic sclerosis.

Authors:  Mohammed Tikly; Kalavati Channa; Penny Theodorou; Mairam Gulumian
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

4.  Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma.

Authors:  C M Stein; S B Tanner; J A Awad; L J Roberts; J D Morrow
Journal:  Arthritis Rheum       Date:  1996-07

5.  Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury.

Authors:  R Solans; C Motta; R Solá; A E La Ville; J Lima; P Simeón; N Montellà; L Armadans-Gil; V Fonollosa; M Vilardell
Journal:  Arthritis Rheum       Date:  2000-04

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

8.  Monocytes of patients wiht systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion.

Authors:  P Sambo; L Jannino; M Candela; A Salvi; M Donini; S Dusi; M M Luchetti; A Gabrielli
Journal:  J Invest Dermatol       Date:  1999-01       Impact factor: 8.551

9.  Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study.

Authors:  Y Niwa; K Somiya; A M Michelson; K Puget
Journal:  Free Radic Res Commun       Date:  1985

Review 10.  Superoxide dismutase and pulmonary oxygen toxicity.

Authors:  M F Tsan
Journal:  Proc Soc Exp Biol Med       Date:  1993-07
View more
  8 in total

Review 1.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

2.  Genistein protects dermal fibrosis in bleomycin-induced experimental scleroderma.

Authors:  Süleyman Serdar Koca; Adile Ferda Dağlı; Servet Yolbaş; Nevzat Gözel; Ahmet Işık
Journal:  Eur J Rheumatol       Date:  2015-05-20

Review 3.  Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?

Authors:  Steven K Huang; Marc Peters-Golden
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

4.  Large leg ulcers due to autoimmune diseases.

Authors:  Alexander P Rozin; Dana Egozi; Yehuda Ramon; Kohava Toledano; Yolanda Braun-Moscovici; Doron Markovits; Daniel Schapira; Reuven Bergman; Yehuda Melamed; Yehuda Ullman; Alexandra Balbir-Gurman
Journal:  Med Sci Monit       Date:  2011-01

Review 5.  Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited.

Authors:  Armando Gabrielli; Silvia Svegliati; Gianluca Moroncini; Giovanni Pomponio; Mariarosaria Santillo; Enrico V Avvedimento
Journal:  Semin Immunopathol       Date:  2008-06-12       Impact factor: 11.759

6.  Systemic sclerosis biomarkers detection in the secretome of TGFβ1-activated primary human lung fibroblasts.

Authors:  Ryan T Kendall; Ludivine Renaud; John E Baatz; Maya Malaab; Xinh-Xinh Nguyen; Carol A Feghali-Bostwick
Journal:  J Proteomics       Date:  2021-04-27       Impact factor: 3.855

7.  Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin.

Authors:  Sonja Hetzer; Bettina Alexandra Buhren; Holger Schrumpf; Edwin Bölke; Stephan Meller; Kai Kammers; Peter Arne Gerber; Bernhard Homey
Journal:  Eur J Med Res       Date:  2014-01-10       Impact factor: 2.175

8.  Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia-reperfusion injury in rats.

Authors:  Dilek Erer; Abdullah Özer; Hüseyin Demirtaş; İpek Işık Gönül; Halil Kara; Hande Arpacı; Faruk Metin Çomu; Gürsel Levent Oktar; Mustafa Arslan; Ayşegül Küçük
Journal:  Drug Des Devel Ther       Date:  2016-08-19       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.